Nuvation Bio Inc. Cash and Cash Equivalents, Period Increase (Decrease)
Nuvation Bio Inc. (NUVB) reported Cash and Cash Equivalents, Period Increase (Decrease) of $908.11 thousand for the 8-month period ending 2020-12-31, per its 10-K/A filed 2021-05-21.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2021-05-21
- 2020-12-31: Cash and Cash Equivalents, Period Increase (Decrease) 8 month $908.11K.
- 2020-09-30: Cash and Cash Equivalents, Period Increase (Decrease) 5 month $1.34M.
- 2020-06-30: Cash and Cash Equivalents, Period Increase (Decrease) 2 month $3.38K.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 2 month | Cash and Cash Equivalents, Period Increase (Decrease) 5 month | Cash and Cash Equivalents, Period Increase (Decrease) 8 month |
|---|---|---|---|
| 2020-12-31 | $908.11K 10-K/A · filed 2021-05-21 | ||
| 2020-09-30 | $1.34M 10-Q · filed 2020-11-16 | ||
| 2020-06-30 | $3.38K 10-Q · filed 2020-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |